EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The History of Cytokines in Rheumatic Disease: An Evolutionary Perspective on Mediators, Inhibitors, and Therapeutics

Stoimen Dimitrov, Simona Bogdanova-Petrova, Zlatimir Kolarov

Rheumatology (Bulgaria) · 19.03.2026 · 33 (4) · 46-74

DOI: 10.35465/0cm8pt95 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology (Bulgaria), online erschienen am 19.03.2026. Verfasst von Stoimen Dimitrov und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytokines are small, secreted proteins that serve as the principal mediators of the immune system, orchestrating the complex interplay of cells involved in inflammation, immunity, and tissue homeostasis. Their dysregulation is a central feature in the pathophysiology of chronic inflammatory conditions, particularly autoimmune rheumatic diseases such as rheumatoid arthritis. This report provides a comprehensive, structured analysis of the history of cytokines, tracing their evolution from vaguely understood biological activities to precisely defined molecular targets for revolutionary therapies. To provide a conceptual foundation, fundamental definitions and classifications of cytokines are established, with a specific focus on how the core properties of pleiotropy, redundancy, and network complexity have profoundly influenced their study and therapeutic manipulation. The narrative subsequently details landmark discoveries of key pathogenic cytokines in rheumatology—including the TNF-α, IL-1, and IL-6 families—while detailing the paradigm shift prompted by the identification of the IL-23/Th17 axis. Parallel to these discoveries, the evolution of therapeutic agents is mapped from first-generation biologic disease-modifying anti-rheumatic drugs (bDMARDs), such as TNF inhibitors, to the oral revolution of targeted synthetic DMARDs like Janus kinase inhibitors, and onward to next-generation strategies including bispecific antibodies and engineered cytokines. In the final sections, the current state of the field is synthesized through a critical examination of unresolved questions and knowledge gaps, such as the mechanisms of treatment non-response, the challenge of cytokine redundancy, and the optimal management of systemic comorbidities. Prospective future directions are outlined, emphasizing an increasing focus on biomarker-driven patient stratification, multi-target combination strategies, and the ultimate pursuit of immune tolerance and curative therapies. Together, these developments represent a clear evolutionary trajectory toward the realization of precision medicine in rheumatology.

Zitieren

APA

Dimitrov, S., Bogdanova-Petrova, S., & Kolarov, Z. (2026). The History of Cytokines in Rheumatic Disease: An Evolutionary Perspective on Mediators, Inhibitors, and Therapeutics. Rheumatology (Bulgaria), 33(4), 46-74. https://doi.org/10.35465/0cm8pt95

Vancouver

Dimitrov S, Bogdanova-Petrova S, Kolarov Z. The History of Cytokines in Rheumatic Disease: An Evolutionary Perspective on Mediators, Inhibitors, and Therapeutics. Rheumatology (Bulgaria). 2026;33(4):46-74. doi:10.35465/0cm8pt95

BibTeX
@article{Dimitrov2026,
  author = {Dimitrov, Stoimen and Bogdanova-Petrova, Simona and Kolarov, Zlatimir},
  title = {The History of Cytokines in Rheumatic Disease: An Evolutionary Perspective on Mediators, Inhibitors, and Therapeutics},
  journal = {Rheumatology (Bulgaria)},
  year = {2026},
  volume = {33},
  number = {4},
  pages = {46--74},
  doi = {10.35465/0cm8pt95}
}
Kostenlos starten →